Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 5/20 | 0.39 |
| ▸ | NPC1 | O15118 | 4/20 | 0.39 |
| ▸ | RAB9A | P51151 | 4/20 | 0.39 |
| ▸ | TSHR | P16473 | 1/20 | 0.39 |
| ▸ | RECQL | P46063 | 1/20 | 0.38 |
| ▸ | MEN1 | O00255 | 4/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.38 |
| ▸ | LMNA | P02545 | 3/20 | 0.35 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.35 |
| ▸ | TP53 | P04637 | 1/20 | 0.35 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.35 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.35 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.35 |
| ▸ | MGLL | Q99685 | 1/20 | 0.35 |
| ▸ | CHRNA7 | P36544 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL965267 | 0.87 | TSHR (0.43) | SMN1; SMN2NPC1RAB9ATSHRRECQL | |
| SCHEMBL2534597 | 0.81 | HPGD (0.48) | SMN1; SMN2NPC1RAB9AMEN1KMT2A | |
| SCHEMBL122020 | 0.78 | SMN1; SMN2 (0.53) | SMN1; SMN2NPC1RAB9ATSHRKMT2A | |
| SCHEMBL5476071 | 0.77 | NPC1 (0.34) | SMN1; SMN2NPC1RAB9ATSHRRECQL | |
| SCHEMBL5477263 | 0.77 | NPC1 (0.34) | SMN1; SMN2NPC1RAB9ATSHRRECQL | |
| SCHEMBL1416126 | 0.77 | HPGD (0.49) | SMN1; SMN2NPC1RAB9AMEN1KMT2A | |
| SCHEMBL964220 | 0.75 | NPC1 (0.45) | SMN1; SMN2NPC1RAB9ATSHRRECQL | |
| SCHEMBL2035775 | 0.75 | NPC1 (0.54) | SMN1; SMN2NPC1RAB9ATSHRLMNA | |
| SCHEMBL1416274 | 0.74 | SMN1; SMN2 (0.46) | SMN1; SMN2NPC1RAB9ATSHRMEN1 | |
| SCHEMBL114046 | 0.74 | MEN1 (0.47) | SMN1; SMN2TSHRMEN1KMT2ANPSR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110245238-A1 | Novel Soluble 1,4 Benzodiazepine Compounds and Stable Salts Thereof | THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) | 2011-10-06 | — | — | US | claimed |
| US-20110009393-A1 | Novel Soluble 1,4 Benzodiazepine Compounds and Stable Salts Thereof | THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) | 2011-01-13 | — | — | US | claimed |
| US-7759338-B2 | Soluble 1,4 benzodiazepine compounds and stable salts thereof | THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) | 2010-07-20 | — | — | US | claimed |
| US-20080064686-A1 | Novel soluble 1,4 benzodiazepine compounds and stable salts thereof | THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) | 2008-03-13 | — | — | US | claimed |
| US-20110245238-A1 | Novel Soluble 1,4 Benzodiazepine Compounds and Stable Salts Thereof | THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) | 2011-10-06 | — | — | US | disclosed |
| US-20110009393-A1 | Novel Soluble 1,4 Benzodiazepine Compounds and Stable Salts Thereof | THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) | 2011-01-13 | — | — | US | disclosed |
| US-7759338-B2 | Soluble 1,4 benzodiazepine compounds and stable salts thereof | THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) | 2010-07-20 | — | — | US | disclosed |
| EP-2152080-A1 | NOVEL SOLUBLE 1,4 BENZODIAZEPINE COMPOUNDS AND STABLE SALTS THEREOF | The Regents of the University of Michigan (US) | 2010-02-17 | — | — | EP | disclosed |
| WO-2008133635-A1 | NOVEL SOLUBLE 1,4 BENZODIAZEPINE COMPOUNDS AND STABLE SALTS THEREOF | THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) | 2008-11-06 | — | — | WO | disclosed |
| US-20080064686-A1 | Novel soluble 1,4 benzodiazepine compounds and stable salts thereof | THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) | 2008-03-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110245238-A1 | Novel Soluble 1,4 Benzodiazepine Compounds and Stable Salts Thereof | GABRA4, BAD, GABRA1 | SMN1; SMN2 2728/4885NPC1 1179/4885RAB9A 3343/4885 |
| US-20080064686-A1 | Novel soluble 1,4 benzodiazepine compounds and stable salts thereof | GABRA4, BAD, GABRA1 | SMN1; SMN2 2728/4885NPC1 1179/4885RAB9A 3343/4885 |
| US-20110009393-A1 | Novel Soluble 1,4 Benzodiazepine Compounds and Stable Salts Thereof | GABRA4, BAD, GABRA1 | SMN1; SMN2 2728/4885NPC1 1179/4885RAB9A 3343/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.